Abstract
Background Pathogenic and likely pathogenic variants associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are recommended to be reported as secondary findings in genome sequencing studies. This provides opportunities for early diagnosis, but also fuels uncertainty in variant carriers (G+), since disease penetrance is incomplete. We assessed the prevalence and disease expression of G+ in the general population.
Methods We identified pathogenic and likely pathogenic variants associated with ARVC, DCM and/or HCM in 200,643 UK Biobank individuals, who underwent whole exome sequencing. We calculated the prevalence of G+ and analysed the frequency of cardiomyopathy/heart failure diagnosis. In undiagnosed individuals, we analysed early signs of disease expression using available electrocardiography and cardiac magnetic resonance imaging data.
Results We found a prevalence of 1:578, 1:251 and 1:149 for pathogenic and likely pathogenic variants associated with ARVC, DCM and HCM respectively. Compared to controls, cardiovascular mortality was higher in DCM G+ (OR 1.67 [95% CI 1.04;2.59], p=0.030), but similar in ARVC and HCM G+ (p≥0.100). Cardiomyopathy or heart failure diagnosis were more frequent in DCM G+ (OR 3.66 [95% CI 2.24;5.81], p=4.9×10−7) and HCM G+ (OR 3.03 [95% CI 1.98;4.56], p=5.8×10−7), but comparable in ARVC G+ (p=0.172). In contrast, ARVC G+ had more ventricular arrhythmias (p=3.3×10−4). In undiagnosed individuals, left ventricular ejection fraction was reduced in DCM G+ (p=0.009).
Conclusions In the general population, pathogenic and likely pathogenic variants associated with ARVC, DCM or HCM are not uncommon. Although G+ have increased mortality and morbidity, disease penetrance in these carriers from the general population remains low (1.2-3.1%). Follow-up decisions in case of incidental findings should not be based solely on a variant, but on multiple factors, including family history and disease expression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was financially supported by the Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation (CardioVasculair Onderzoek Nederland (CVON) projects: DOUBLE-DOSE 2020B005 (AB), PREDICT2 2018-30, eDETECT 2015-12 (PvT, AtR and FA) and PREDICT Young Talent Program (AtR)). In addition, this work was supported by the Dutch Heart Foundation (2015T058 (AtR), 2015T041 (AB) and 2019T045 (MvV and JvS)). Furthermore, MB is supported by the Alexandre Suerman Stipend of the UMC Utrecht (2017), AtR by the UMC Utrecht Fellowship Clinical Research Talent and FA by the UCL Hospitals NIHR Biomedical Research Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the UK Biobank study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382) and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Non-standard Abbreviations and Acronyms
- ACMG
- American College of Medical Genetics and Genomics
- ACTC1
- Actin Alpha Cardiac Muscle 1
- ACTN1
- Alpha-actinin 2
- AHA
- American Heart Association
- ARVC
- Arrhythmogenic right ventricular cardiomyopathy
- BAG3
- BAG Cochaperone 3
- BMI
- Body mass index
- CI
- Confidence interval
- ClinGen
- Clinical Genome Resource
- CMR
- Cardiac magnetic resonance imaging
- CSRP3
- Cysteine And Glycine Rich Protein 3
- DCM
- Dilated cardiomyopathy
- DES
- Desmin
- DSC2
- Desmocollin 2
- DSG2
- Desmoglein 2
- DSP
- Desmoplakin
- ECG
- Electrocardiography
- EDM
- End diastolic mass
- EDV
- End diastolic volume
- EF
- Ejection fraction
- ESV
- End systolic volume
- FLNC
- Filamin-C
- G+
- Genotype positive (variant carriers)
- G-
- Genotype negative (controls)
- i
- Indexed, corrected for body surface area
- JPH2
- Junctophilin 2
- JUP
- Junction Plakoglobin
- HCM
- Hypertrophic cardiomyopathy
- LMNA
- Lamin A/C
- LoF
- Loss of function
- LV
- Left ventricular
- MAF
- Minor allele frequency
- MET
- Metabolic equivalent of task minutes
- MVR
- Mass to EDV ratio
- MYBPC3
- Myosin Binding Protein C3
- MYH7
- Myosin Heavy Chain 7
- MYL2
- Myosin Light Chain 2
- MYL3
- Myosin Light Chain 3
- NEXN
- Nexilin F-Actin Binding Protein
- NGS
- Next generation sequencing
- OR
- Odds ratio
- P+
- Phenotype positive
- P-
- Phenotype negative
- PKP2
- Plakophilin 2
- PLN
- Phospholamban
- RBM20
- RNA Binding Motif Protein 20
- RV
- Right ventricular
- SCN5A
- Sodium Voltage-Gated Channel Alpha Subunit 5
- SD
- Standard deviation
- SV
- Stroke volume
- TFC
- Task force criteria
- TMEM43
- Transmembrane Protein 43
- TNNC1
- Troponin C1, Slow Skeletal And Cardiac Type
- TNNI3
- Troponin I3, Cardiac Type
- TNNT2
- Troponin T2, Cardiac Type
- TPM1
- Tropomyosin 1
- TTN
- Titin
- UKB
- UK Biobank
- VKGL
- Vereniging Klinische Genetische Laboratoriumdiagnostiek
- VCL
- Vinculin
- WES
- Whole exome sequencing
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.